Drug intelligence / Profile preview

COVIDEX

Development stage: Phase 2
Lead developer: Jena Herbals Uganda
Administration: Topical, Oral

Overview

COVIDEX is a herbal formulation developed in Uganda for the supportive treatment of COVID-19. It contains berberine as a primary anti-SARS-CoV-2 compound and is currently undergoing investigation for its safety and efficacy in managing adult COVID-19 patients.

Brand names: COVIDEX

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on COVIDEX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVIDEX.

Explore the full profile